Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Autor: Matthias Scheffler, Thomas Zander, Lucia Nogova, Carsten Kobe, Deniz Kahraman, Markus Dietlein, Irini Papachristou, Lukas Heukamp, Reinhard Büttner, Ron Boellaard, Adriaan A Lammertsma, Silvia Querings, Erich Stoelben, Walburga Engel-Riedel, Bernd Neumaier, Jürgen Wolf

Publikováno v: PLoS ONE, Vol 8, Iss 1, p e53081 (2013)

3'-deoxy-3'-[(18)F]fluoro-L-thymidine (FLT) and 2'-deoxy-2'-[(18)F]fluoro-D-glucose (FDG) are used to visualize proliferative and metabolic activity of tumors. In this study we aimed at evaluating the prognostic value of FLT and FDG uptake measured b

Externí odkaz: https://doaj.org/article/ea9dfc6ca85d493eb465281389a28e09

Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [(18)F]Fluorodeoxyglucose and [(18)F]Fluorothymidine Positron Emission Tomography

Autor: Reinhard Buettner, Lukas C. Heukamp, Walburga Engel-Riedel, Thomas Zander, Egbert Smit, Irini Papachristou, Roman K. Thomas, Andreas H. Jacobs, Markus Dietlein, Karin Toepelt, Adriaan Lammertsma, Andreas Draube, Martin Hellmich, Juergen Wolf, Erich Stoelben, Matthias Scheffler, Silvia Querings, Roland T. Ullrich, Karin Schulte, Yon D. Ko, Carsten Kobe, Ronald Boellaard, Lucia Nogova, Michael Hallek, Bernd Neumaier, Andreas Schlesinger

Publikováno v: Zander, T, Scheffler, M, Nogova, L, Kobe, C, Engel-Riedel, W, Hellmich, M, Papachristou, I, Toepelt, K, Draube, A, Heukamp, L, Buettner, R, Ko, Y D, Ullrich, R T, Smit, E F, Boellaard, R, Lammertsma, A A, Hallek, M, Jacobs, A H, Schlesinger, A, Schulte, K, Querings, S, Stoelben, E, Neumaier, B, Thomas, R K, Dietlein, M & Wolf, J 2011, ' Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [(18)F]Fluorodeoxyglucose and [(18)F]Fluorothymidine Positron Emission Tomography ', Journal of Clinical Oncology, vol. 29, no. 13, pp. 1701-1708 . https://doi.org/10.1200/JCO.2010.32.4939
Journal of Clinical Oncology, 29(13), 1701-1708. American Society of Clinical Oncology

Purpose Positron emission tomography (PET) with both 2′-deoxy-2′-[18F]fluoro-d-glucose (FDG) and 3′-[18F]fluoro-3′-deoxy-l-thymidine (FLT) was evaluated with respect to the accuracy of early prediction of nonprogression following erlotinib th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9604a21f24ac1acffe8e95f2c96803f
https://research.vumc.nl/en/publications/e2fdda8e-54e6-4f9c-afef-31a344e84680

MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab

Autor: Walburga Engel-Riedel, Markus Dietlein, Bernd Neumaier, Irini Papachristou, Thomas Zander, Martin L. Sos, Deniz Kahraman, Matthias Scheffler, Marc Bos, Lukas C. Heukamp, Adriaan A. Lammertsma, Christian Mattonet, Juergen Wolf, Erich Stoelben, Reinhard Büttner, Carsten Kobe, Thomas Elter, Karin Toepelt, Ronald Boellaard, Lucia Nogova

Publikováno v: Journal of Clinical Oncology. 30:7603-7603

7603 Background: Since the introduction of targeted therapy into the treatment of NSCLC, molecular imaging tools gain in importance for assessment of pharmacodynamics, pharmacokinetics and prediction of therapeutic outcome. Tumor metabolism (by FDG-P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fee798424de03db0970eff57c428294f
https://doi.org/10.1200/jco.2012.30.15_suppl.7603

[18F]fluoro-L-thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced non-small cell lung cancer (NSCLC) treated first-line with erlotinib

Autor: Irini Papachristou, Juergen Wolf, Carsten Kobe, Bernd Neumaier, Thomas Zander, Matthias Scheffler, Deniz Kahraman, Silvia Querings, Lucia Nogova, Markus Dietlein, Walburga Engel-Riedel, Erich Stoelben

Publikováno v: Journal of Clinical Oncology. 29:7591-7591

7591 Background: Since the introduction of targeted therapy into the treatment of advanced NSCLC molecular imaging tools gain in importance for assessment of pharmacodynamics, prognosis and predict...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fa84291e1759688e0d20160b4548272
https://doi.org/10.1200/jco.2011.29.15_suppl.7591

SORAVE trial: Phase I sorafenib and everolimus in solid tumors

Autor: Christian Mattonet, Irini Papachristou, Juergen Wolf, Matthias Scheffler, Ildiko Katay, Lucia Nogova, Peter Mallmann, Uwe Fuhr, Markus Dietlein, R. Krais

Publikováno v: Journal of Clinical Oncology. 28:TPS170-TPS170

TPS170 Background: Clinical efficacy of the multikinase inhibitor sorafenib is mainly based on its antiangiogenic properties mediated by VEGFR inhibition. The mTOR inhibitor everolimus also exerts ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e2800fb44745a881fa71b45e61f0e19
https://doi.org/10.1200/jco.2010.28.15_suppl.tps170